Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prediction of outcome in patients with chronic obstructive pulmonary disease

A patient and prognostic technology, applied in the field of clinical diagnostics, can solve the problems of unknown prognostic value of biomarkers, lack of risk stratification strategy for ambulatory patients, etc.

Active Publication Date: 2017-03-01
BRAHMS GMBH
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prognostic value of such biomarkers in stable disease remains unknown and risk stratification strategies for ambulatory patients are lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prediction of outcome in patients with chronic obstructive pulmonary disease
  • Prediction of outcome in patients with chronic obstructive pulmonary disease
  • Prediction of outcome in patients with chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0125] marker measurement

[0126] MR-proANP was detected using a novel fully automated sandwich immunoassay system on the B.R.A.H.M.S KRYPTOR (B.R.A.H.M.S GmbH, Hennigsdorf / Berlin, Germany). The stochastic on-line analyzer uses a sensitive Time Resolved Amplified Cryptate Emission (TRACE) technique based on the non-radioactive transfer between 2 fluorophores, europium cryptate and XL665. This automated assay is essentially based on a sandwich chemiluminescent assay described in detail elsewhere ( Morgenthaler et al 2004.Clin Chem50:234-6 ), and for other studies ( Khan et al. 2008. J Am Coll Cardiol 51:1857-64; Gegenhuber et al. 2006. Clin Chem 52: 827-31 ). For MR-proANP detection, 14 μl of patient serum was incubated for 14 min. The measurement range is 0-10000pmol / L, the detection limit is 2.1pmol / L, and the quantification limit is 4.5pmol / L. The intra-assay CV was 1.2% and the inter-laboratory CV was 5.4%. This assay uses the same antibody pair as the reference...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for prognosis and / or risk assessment and / or monitoring in the treatment and / or management of COPD patients, said method comprising the steps of: i) providing a sample of body fluid from said patient, ii) determining said The level of at least one biomarker in the sample selected from proadrenomedullin (proADM), pronatriuretic peptide, provasopressin (proAVP) and procalcitonin (PCT) or their length iii) determination of the BODE-index parameters body mass index (BMI, parameter B), degree of airflow obstruction (FEV1, parameter O), dyspnea (parameter D) and exercise capacity (parameter E) 1, 2 or 3, iv) correlating said levels of said at least one biomarker determined in step ii) in combination with said 1, 2 or 3 BODE index parameters determined in step iii) with COPD Associated with prognosis and / or risk scoring and / or monitoring of patient treatment and / or management.

Description

[0001] field of invention [0002] The present invention is in the field of clinical diagnostics. In particular, the present invention relates to the determination of biomarker levels in samples derived from bodily fluids of COPD patients. [0003] Background of the invention [0004] Chronic obstructive pulmonary disease (COPD), a generally preventable and treatable disease, is characterized by persistent airflow limitation that is often progressive and associated with an enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases . Symptoms of COPD include dyspnea, prolonged cough and chronic expectoration. Spirometry is required to make a clinical diagnosis of COPD. Post-bronchiectasis FEV less than 0.70 1 The presence of / FVC (forced expiratory volume in 1 second / forced vital capacity) confirms the presence of persistent airflow limitation and thus COPD. [0005] The prevalence of clinically relevant COPD is approximately 4–6% in the E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/74
CPCG01N33/6884G01N33/6893G01N33/74G01N2800/122G01N2800/52G01N2333/58G01N33/68G01N2333/585G01N2800/50
Inventor S·吉尔斯多夫M·塔姆D·斯托尔兹
Owner BRAHMS GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com